Twitxy
Saved
@Inside_PM's profile picture
View on X

Inside Precision Medicine

@Inside_PM

Exclusive news, features, and analysis on the research, tools, regulations, and applications driving precision medicine. From the publisher of @GENBio
New Rochelle, NY insideprecisionmedicine.com Joined April 2014
1.3K Following 5.5K Followers 21K Posts

Latest posts 5

Inside Precision Medicine @Inside_PM
Surveillance Mammography Doesn't Improve Survival in Older Women with Breast Cancer History

Additional follow-up mammograms do not reduce the risk of advanced second primary breast cancer among older patients
@YaleMed
#breastcancer #diagnosticimaging
hubs.li/Q04DF7L00
www.insideprecisionmedicine.com Surveillance Mammography Doesn't Improve Survival in Older Women with Breast Cancer History Additional follow-up mammograms do not reduce the risk of advanced second primary breast cancer among older patients, even among those who were treated for hormone receptor positive disease.
Inside Precision Medicine @Inside_PM
New PET Scan Technology Identifies Hidden Myeloma Cells Missed on Conventional Scans

A new CD38-targeted #PETscan detects multiple #myeloma missed by conventional imaging, potentially improving disease monitoring and treatment decisions
@univmiami
hubs.li/Q04DF6ly0
www.insideprecisionmedicine.com New PET Scan Technology Identifies Hidden Myeloma Cells Missed on Conventional Scans A new CD38-targeted PET scan detects multiple myeloma missed by conventional imaging, potentially improving disease monitoring and treatment decisions.
Inside Precision Medicine @Inside_PM
Insilico’s AI-Designed Mesothelioma Treatment Shows Early Promise

@InSilicoMeds reports good early safety and efficacy results for its AI-designed mesothelioma treatment ISM6331

#AI #drugdesign #mesothelioma #smallmolecule
hubs.li/Q04DF4B30
www.insideprecisionmedicine.com Insilico’s AI-Designed Mesothelioma Treatment Shows Early Promise Insilico reports good early safety and efficacy results for its AI-designed mesothelioma treatment ISM6331.
Inside Precision Medicine @Inside_PM
New Standard-of-Care for KRAS G12C-Mutated Advanced NSCLC

Phase III results show improved survival with divarasib versus current treatments in previously treated KRAS G12C-mutated advanced lung cancer
@UTMDAnderson
#NSCLC #clinicaltrial
hubs.li/Q04DF06V0
www.insideprecisionmedicine.com New Standard-of-Care for KRAS G12C-Mutated Advanced NSCLC Phase III results show improved survival with divarasib versus current treatments in previously treated KRAS G12C-mutated advanced lung cancer.